Abstract 1480P
Background
Bone metastases (BM) due to breast cancer are associated with a high risk of pain and skeletal related events (SREs= pathological fractures, spinal cord compression, hypercalcemia). Treatment of BM includes radiotherapy (RT), bone surgery (BS), anticancer and antiresorptive drugs. The aim of the study was to compare zoledronic acid (ZA) and denosumab (Dmab) in reducing first SRE and bone pain in breast cancer patients with BM.
Methods
This monocentric retrospective study included breast cancer patients with bone metastases that received at least 24 infusions of ZA or Dmab, between January 2008 and January 2023. The endpoints were: occurrence of a SREs or RT/BS need, change in anticancer therapy, week average pain intensity, level of analgesic drug used (according to the WHO three-step analgesic ladder) and the opioid dose (using oral morphine equivalent mg, OME). These endpoints were evaluated during ZA or Dmab therapy. To evaluate the analgesic effect, three Bayesian longitudinal mixed effects models were implemented having as response variable the WHO ladder drug level, the pain intensity, and the OME. All models shared the same covariates and multiple regression models were used to study the associations.
Results
The study enrolled 364 patients (194 ZA and 170 Dmab). Dmab and ZA had a comparable effect on first SRE occurrence and on RT/BS referral incidence. The cumulative incidence of the first SRE was equal to 28.9% (24.2%-33.7%). At 1 and 2 years the cumulative incidence for the first SRE and the need of RT/BS was similar for AZ and Dmab (p=0.6, p> 0.9 respectively). In the three models Dmab had a significant analgesic effect respect to ZA: patients on Dmab were 89% less likely to increase one step on the WHO ladder. They also showed a reduction on average of 0.4 points (-0.67, -0.12, 95% CI) on the numerical rating scale. Finally, patients on Dmab took an average 0.77 mg OME dose (0.22-2.94, 95% CI) compared with 6.24 mg OME dose (3.6- 18, 95% CI) of ZA patients.
Conclusions
Dmab had a greater impact on preventing and reducing bone pain in breast cancer patients rather than ZA. However, long term AZ and Dmab were similar in preventing the first SRE and RT/BS need.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale dei tumori.
Funding
Has not received any funding.
Disclosure
E. Zecca: Other, Institutional, Invited Speaker: Amgen. A.T. Caraceni: Other, Institutional, Invited Speaker: Angelini, Shionogi, Kyowa Kirin, Molteni, Pfizer, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10